RICTOR (rapamycin‐insensitive companion of mTOR) has been found to be overexpressed in various cancers (e.g., gastric and lung) and to be capable of cooperating with other driver mutations to stimulate cellular proliferation (Cheng et al., 2015; Kim et al., 2016; Morrison Joly et al., 2016). Here, RICTOR is linked to cancer.